Gait retraining involves making a small adjustment to the angle of your foot — a minor change that can yield major benefits, ...

Exercise finds improvements in pain and function may fall short of what patients would notice in daily life, but more studies ...

Kolon TissueGene’s stock dropped nearly 30% after the Phase III knee osteoarthritis trial failure.

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

Dr. Ashutosh Jha discusses risk factors for knee degeneration, robotic-assisted Total Knee Replacement and the role of timely evaluation in improving mobility and function.

Millions of people with knee osteoarthritis live with daily pain and stiffness that erode their ability to walk, climb stairs ...

July 17, 2026. More for You ...

Scientists regrew knee cartilage by blocking an aging protein, opening a promising path for future osteoarthritis treatments.

But if precautions aren’t taken, pain and injuries can follow. When it comes to knee pain, it’s women who are feeling the brunt of the agony. And while women have higher instances of knee injury than ...

Patients with "bone-on-bone" arthritis, PRP produced sustained pain and function and measurable shifts in cartilage ...

Joint Genesis Reviews examine a synovial fluid formula backed by 14 Mobilee trials and a verifiable U.S. Army physician ...

ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month 12Results from ACTiVION-I, the second Phase 3 trial of ...